Pharma Stocks: Gilead Sciences Inc has priced its covid-19 antiviral remdesivir at $2,340 per patient for wealthier nations. The US-based pharma company has linked up with generic drugmakers based in…
Read More

Leave a comment

Your email address will not be published. Required fields are marked *